phomas are transformed into large cell lymphomas they no longer need T cell stimulation to maintain their continuous progression; however, while they are lymphomas of low-grade malignancy they need stimulation from HP-specific T cells. This hypothesis explains the tendency for gastric MALT lymphomas to stay in the stomach where HP provides antigenic stimulation, and it also explains why elimination of HP is sometimes effective in causing MALT lymphomas of lowgrade malignancy to regress. In the current case, the number of mutations observed was almost identical with that of the expected value, as shown in Table 2 , calculated as it occurs at random. 8 This indicated proliferation of lymphoma cells not selected by any specific antigenic stimulation, in other words, no specific variant of a lymphoma clone was growing. This must be one of the important reasons why this tumor spread widely without being transformed to a large cell-type high-grade lymphoma.
Such lymphoproliferative disorders may arise not only in gastric tissue but also in other mucosal areas such as ocular, bronchial and prostatic regions. The term 'pseudolymphoma' has been used for those disorders, such as 'RLH' in the stomach. Recent studies using Southern blot analysis demonstrated that they consist of monoclonal B cell proliferation leading to diagnoses of lymphomas with low-grade malignancy. In addition to gastric cases, proliferation of MALT lymphomas in other organs may correlate with some specific antigenic stimulation. Thus, it would be of great value to consider this concept in detail with the aim of developing a new and effec-
Clonal myelodysplastic cells present in apheresis product before transplantation

TO THE EDITOR
Over the last few years several reports of secondary acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) have been published describing serious complications of autologous hematopoietic stem cell transplantation with an actuarial incidence ranging from 1 to 18%. [1] [2] [3] [4] [5] Although these cases are usually reported under the heading of secondary MDS following hematopoietic stem cell transplantation, it is debatable whether this complication is due to the transplantation procedure (conditioning regimen), or to the chemotherapy used prior to transplantation for the treatment of the underlying malignant disorder. Moreover, to the best of our knowledge it has not been shown that the hematopoietic stem cells harvested for the transplant already carried the clonal marker (cytogenetic or molecular abnormality) detected in the secondary MDS.
We report a patient with a B cell non-Hodgkin's lymphoma who developed a MDS 27 months after autologous peripheral blood stem cell transplantation. Cytogenetic analysis performed on bone marrow cells at the time of MDS diagnosis showed two abnormal clones: 44,XX,−5,dic(7;15) (p11;p11) and 45,XX,−15,add(16)p(13). Using fluorescence in situ hybridization (FISH) it was possible to demonstrate that the clonal karyotypic abnormalities were already present in the leukapheresis product.
A 47-year-old woman presented with stage IV-B centrocytic-centroblastic non-Hodgkin's lymphoma (grade 2 follicular according to REAL classification). Following treatment with the PROMACE/MOPP scheme × 6 cycles, a partial remission was obtained. Stem cell mobilization was carried out with cyclophosphamide 4 g/m 2 followed by G-CSF 5 g/kg. A second mobilization procedure was required in order to obtain sufficient progenitor cells. It was performed in stable phase with administration of G-CSF at 10 g/kg. /l) and bone marrow differential counts were normal, without signs of myelodysplastic changes. She had prolonged delay in myeloid engraftment with neutrophil recovery greater than 1 × 10 9 /l at day +60 after transplantation and she remained thrombocytopenic (platelet counts between 50-100 × 10 9 /l) but was otherwise asymptomatic. Morphological examination of bone marrow 6 and 12 months after autologous transplantation did not show myelodysplastic features. Twenty-seven months after transplantation a drop in blood counts was observed: hemoglobin 96 g/l, WBC 2 × 10 9 /l (28% polymorphonuclear leukocytes, 63% lymphocytes, 2% monocytes, 2% bands, 2% metamyelocytes, 3% myelocytes) and platelets of 36 × 10 9 /l. Bone marrow aspirate showed 22% of blast cells with dysgranulopoiesis and dysthrombopoiesis. A diagnosis of refractory anemia with excess of blasts in transformation (RAEB-t) was made according to FAB classification. No clinical, histological or radiological evidence of lymphoma was detected.
At this point the karyotype showed two abnormal clones: one with 44,XX,−5,dic(7;15)(p11;p11) [13] and the other with 45,XX,−15,add(16)p(13) [7] , while a normal clone 46,XX was present in one metaphase. FISH of this sample confirmed the two clones: 73% of cells displayed monosomy 15 and 20% with dic(7;15). A retrospective FISH analysis of an aliquot sample of the cryopreserved peripheral blood stem cells used for transplantation showed that the chromosomal alterations observed 27 months after transplantation were already present in the harvested cells, with the two abnormal clones: 19% of cells had monosomy 15 and 34% of cells had dic(7;15). In addition, a cryopreserved bone marrow sample corresponding to the bone marrow obtained 6 months after transplantation, which did not show MDS features after morphological examination, was also available. FISH analysis of this sample showed: 22% cells with monosomy 15 and 23% with dic(7;15) ( Figure 1) . The remaining cells showed a normal karyotype. The present report raises one question which has arisen in a large number of reports in recent years; [1] [2] [3] [4] [5] What is the cause of these secondary MDS: the transplant procedure, mainly the conditioning regimen, or the previous therapy used for the treatment of the underlying disorders?
Although most of these cases are reported as secondary to autologous stem cell transplantation, implying that the high dose of chemotherapy used for the conditioning regimen has played a major role in the emergence of MDS, 1-3 some authors already pointed out that chemotherapy used prior to the transplantation procedure, particularly alkylating agents, could be the most important risk factor for the subsequent development of the complication. [2] [3] [4] [5] Nevertheless, to the best of our knowledge, investigations to demonstrate whether the clonal abnormalities were already present in hematopoietic cells obtained prior to conditioning treatment used for transplantation have failed. 1, 6 We report on a patient with MDS diagnosed after autologous transplantation in whom it was demonstrated using FISH, that the clonal alteration was present in the stored cells used for transplantation. Interestingly, at the time of MDS diagnosis the clone with monosomy 15 predominated in contrast with the results obtained in the apheresis. We must emphasize the time that elapsed between autologous transplantation and the development of the clinical manifestations of the MDS. It could be hypothesized that during the first months after transplantation normal or almost normal hematopoiesis took place because at 6 months more than 50% of cells showed a normal karyotype. After that, clonal hematopoiesis expanded more proliferatively than the normal one. To the best of our knowledge, this is the first report which shows that the infused cells had the same clonal karyotypic alteration as the myelodysplastic cells that emerged 27 months after transplantation, and confirms the hypothesis that, at least in some patients, the MDS is secondary to the therapy received before transplantation. Although karyotypic analysis prior to transplantation is already performed in many centres, according to the literature this is not a systematic approach. However, from our data, we consider the analysis mandatory for all patients before autografting in order to detect stem cell damage so that patients at risk of developing therapy-related hematopoietic disorders can be identified. Moreover, our case illustrates the importance of collecting hematopoietic stem cells as soon as possible, in the course of therapy, in order to minimize the risk of harvesting cells with MDS-associated chromosomal changes.
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Identification of a BCR polymorphism in a bone marrow donor: diagnostic implications
TO THE EDITOR
The Philadelphia chromosome (Ph 1 ) is a characteristic cytogenetic feature of chronic myelogenous leukemia (CML), involving reciprocal translocation of the ABL proto-oncogene on chromosome 9 to the breakpoint cluster region (BCR) of chromosome 22. The gene rearrangement may be detected by a number of different molecular diagnostic methods, such as genomic Southern hybridization (GSH) for a non-germline BCR pattern or RT-PCR for the presence of a BCR/ABL fusion transcript.
For patients with CML, high-dose chemotherapy followed by allogeneic bone marrow transplant (BMT) is the preferred treatment when a histocompatible donor is available. Such patients are subsequently monitored for the presence of a BCR gene rearrangement, detection of which is predictive of relapse. Interpretation of test results obtained by RT-PCR is straightforward. A positive result is marked by the presence of a sequence-specific BCR/ABL product and a negative result shows the absence of such a product, when the RNA integrity has been confirmed with a standard PCR primer set. GSH interpretation is more complex and requires, for a sample to be considered positive for a BCR rearrangement, that it either demonstrate a non-germline hybridization pattern with more than one enzyme or that a single positive enzyme generate bands of unequal intensity. This latter assay, although potentially more problematic, provides semi-quantitative data not obtainable by RT-PCR analysis, and this information may prove useful in following patients being treated on a clinical trials protocol.
We report here the diagnostic implications of such a case in which a BMT patient exhibited an apparent BCR gene rearrangement following transplant. The altered band pattern was in fact the result of a previously reported BamHI 1,2 consti-tutional polymorphism in the donor DNA, identified by GSH in the setting of mixed chimerism.
A 27-year-old black male was diagnosed with CML in chronic phase, with the karyotype 46,XY,t(9;22)(q34;q11) [20] , and received an allogeneic BMT from his HLA-matched 26-year-old sister. The preparative regimen for transplantation included cyclophosphamide 50 mg/kg for 4 days and total body irradiation 300 cGy/day for 4 days. Prior to transplant, the patient-donor pair was found to be informative with a locus-specific hypervariable DNA probe, MS-1 (9), which subsequently was utilized to monitor the success of bone marrow engraftment. The patient's DNA sample at this time was negative by GSH for a BCR gene rearrangement using a 600 bp probe for the 5Ј region of the BCR gene, presumably because pre-BMT therapy reduced the disease burden below the 5% detection limit of the Southern blot, and no RT-PCR assay for BCR/ABL was requested or performed. Cyclosporine was given as prophylaxis for graft-versus-host disease beginning 2 days prior to marrow infusion and was continued throughout the patient's course. There was no evidence of graft-versushost disease. During the first 150 days after transplantation, the clinical impression was one of poor engraftment of unclear etiology; total WBC at 30, 90, 120, and 150 days was 215, 500, 1400 and 1600/mm 3 , respectively, with the patient receiving frequent red blood cell and platelet transfusions. G-CSF was given beginning on day 100 and continued until WBC improved. No further red cell or platelet transfusions were required after 6 months.
After BMT the patient was followed at regular intervals by molecular diagnostics for engraftment and/or BCR gene rearrangement. Bone marrow specimens assayed with the MS-1 probe at 30 and 90 days showed evidence of mixed chimerism of 40-45% and 45-50% host, respectively (Figure 1) . At 30 days post-BMT there was no indication by RT-PCR of a BCR/ABL transcription product using a published method
